Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000545-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Immunogenicity Objective To evaluate the antibody response to each influenza vaccine antigen after vaccination with the TIV vaccine, as measured by single radial hemolysis (SRH) or hemagglutination inhibition (HI) assay in accordance with Guidance CPMP/BWP/214/96 Safety Objective To evaluate the safety of TIV in adult subjects in compliance with the requirements of the current European Union recommendations for clinical trials related to yearly licensing of influenza vaccines (CPMP/BWP/214/96)


Critère d'inclusion

  • Influenza

Liens